The parallel lives of angiogenesis and immunosuppression: Cancer and other tales

Nature Reviews Immunology

Volumn 11, Issue 10, 2011, Pages 702-711

  Motz, Gregory T ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALPHA INTERFERON; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CHEMOKINE RECEPTOR CCR10; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; ENDOTHELIN 1; FAS LIGAND; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROPILIN 1; PLATELET DERIVED GROWTH FACTOR; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; BONE MARROW CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; ENDOMETRIUM CANCER; ENDOTHELIUM; HEMATOPOIESIS; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOREGULATION; KIDNEY CARCINOMA; LEUKOCYTE ADHERENCE; LYMPHOCYTE SUBPOPULATION; MAST CELL; MEDIATOR; MESENCHYMAL STEM CELL; MONOCYTE; MYELOID PROGENITOR CELL; NEUTROPHIL; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STROMA CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; WOUND HEALING;

ANIMALS; CELL COMMUNICATION; CYTOKINES; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MYELOID CELLS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 80053159303     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3064     Document Type: Review

References (143)

1. Szekanecz, Z. & Koch, A. E. Mechanisms of disease: angiogenesis in inflammatory diseases. Nature Clin. Pract. Rheumatol. 3, 635-643 (2007). (Pubitemid 350031753)
2. Yang, L. et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004). (Pubitemid 39361441)
3. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005). (Pubitemid 40488632)
4. Riboldi, E. et al. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J. Immunol. 175, 2788-2792 (2005). (Pubitemid 41170494)
5. Hanna, J. et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nature Med. 12, 1065-1074 (2006). (Pubitemid 44353388)
6. Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S. & Weiss, S. Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 120, 1151-1164 (2010).
7. Shrestha, B. et al. B cell-derived vascular endothelial growth factor A promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. J. Immunol. 184, 4819-4826 (2010).
8. Qin, Z. et al. B cells inhibit induction of T cell-dependent tumor immunity. Nature Med. 4, 627-630 (1998). (Pubitemid 28237366)
9. Facciabene, A. et al. Tumour hypoxia promotes tolerance and angiogenesis via Ccl28 and Treg cells. Nature 475, 226-230 (2011).
10. Buckanovich, R. J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Med. 14, 28-36 (2008).
11. West, X. Z. et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467, 972-976 (2010).
12. Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010).
13. Kandalaft, L. E., Powell, D. J. Jr, Singh, N. & Coukos, G. Immunotherapy for ovarian cancer: what's next? J. Clin. Oncol. 29, 925-933 (2010).
14. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
15. Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777-2790 (2006). (Pubitemid 44511641)
16. Huang, B. et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006). (Pubitemid 43165981)
17. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007). (Pubitemid 350231321)
18. Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev. Cancer 8, 618-631 (2008).
19. Conejo-Garcia, J. R. et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature Med. 10, 950-958 (2004). (Pubitemid 39273736)
20. Sica, A. et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J. Immunol. 164, 762-767 (2000). (Pubitemid 30043699)
21. Burke, B. et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol. 163, 1233-1243 (2003). (Pubitemid 37175073)
22. Dirkx, A. E., Oude Egbrink, M. G., Wagstaff, J. & Griffioen, A. W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80, 1183-1196 (2006). (Pubitemid 44904956)
23. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004). (Pubitemid 39273735)
24. Giatromanolaki, A. et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol. Oncol. 110, 216-221 (2008).
25. Gupta, S., Joshi, K., Wig, J. D. & Arora, S. K. Intratumoral FOXP3 expression in infiltrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. Acta Oncol. 46, 792-797 (2007). (Pubitemid 47123764)
26. Freeman, M. R. et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 55, 4140-4145 (1995).
27. Stabile, E. et al. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation 108, 205-210 (2003). (Pubitemid 36871304)
28. Huang, M. T. et al. Regulatory T cells negatively regulate neovasculature of airway remodeling via DLL4-Notch signaling. J. Immunol. 183, 4745-4754 (2009).
29. Bourbie-Vaudaine, S., Blanchard, N., Hivroz, C. & Romeo, P. H. Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J. Immunol. 177, 1460-1469 (2006). (Pubitemid 44092479)
30. Sarris, M., Andersen, K. G., Randow, F., Mayr, L. & Betz, A. G. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28, 402-413 (2008).
31. Inoue, S., Leitner, W. W., Golding, B. & Scott, D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 66, 7741-7747 (2006). (Pubitemid 44289234)
32. Halder, R. C., Aguilera, C., Maricic, I. & Kumar, V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Invest. 117, 2302-2312 (2007). (Pubitemid 47219575)
33. Lu, L. et al. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 26, 593-604 (2007). (Pubitemid 46756350)
34. Wakita, D. et al. Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927-1937 (2010).
35. Angeli, V. et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24, 203-215 (2006). (Pubitemid 43214589)
36. Kalkunte, S. S. et al. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J. Immunol. 182, 4085-4092 (2009).
37. Kyriakakis, E. et al. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur. J. Immunol. 40, 3268-3279 (2010).
38. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nature Rev. Cancer 6, 392-401 (2006).
39. Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725 (1998). (Pubitemid 28436004)
40. Bottazzi, B., Walter, S., Govoni, D., Colotta, F. & Mantovani, A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 1280-1285 (1992).
41. Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337 (2004). (Pubitemid 39551661)
42. da Silva Meirelles, L., Caplan, A. I. & Nardi, N. B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26, 2287-2299 (2008).
43. Krampera, M. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722-3729 (2003). (Pubitemid 36857965)
44. Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005). (Pubitemid 40223708)
45. Ringden, O. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, 1390-1397 (2006). (Pubitemid 43847148)
46. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev. Cancer 8, 579-591 (2008).
47. Della Porta, M. et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 68, 276-284 (2005). (Pubitemid 41158987)
48. Takahashi, A. et al. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother. 53, 543-550 (2004). (Pubitemid 38680261)
49. Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996). (Pubitemid 26338628)
50. Ishida, T., Oyama, T., Carbone, D. P. & Gabrilovich, D. I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol. 161, 4842-4851 (1998). (Pubitemid 28492062)
51. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9, 562-567 (2003). (Pubitemid 36597102)
52. Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878-4886 (2003). (Pubitemid 36857749)
53. Huang, Y. et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110, 624-631 (2007). (Pubitemid 47105401)
54. Shin, J. Y., Yoon, I. H., Kim, J. S., Kim, B. & Park, C. G. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell. Immunol. 256, 72-78 (2009).
55. Li, B. et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12, 6808-6816 (2006). (Pubitemid 44876851)
56. Suzuki, H. et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur. J. Immunol. 40, 197-203 (2010).
57. Montesinos, M. C., Shaw, J. P., Yee, H., Shamamian, P. & Cronstein, B. N. Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am. J. Pathol. 164, 1887-1892 (2004). (Pubitemid 38669338)
58. Alfranca, A. et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFβ/Alk5 signaling pathway. Blood 112, 1120-1128 (2008).
59. Lebrin, F., Deckers, M., Bertolino, P. & Ten Dijke, P. TGF-β receptor function in the endothelium. Cardiovasc. Res. 65, 599-608 (2005).
60. Zanin-Zhorov, A. et al. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J. Clin. Invest. 116, 2022-2032 (2006). (Pubitemid 44033326)
61. Manicassamy, S. et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nature Med. 15, 401-409 (2009).
62. Yamazaki, S. et al. TLR2-dependent induction of IL-10 and Foxp3+CD25+CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS ONE 6, e18833 (2011).
63. Oldford, S. A. et al. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 185, 7067-7076 (2010).
64. Imanishi, T. et al. Cutting edge: TLR2 directly triggers Th1 effector functions. J. Immunol. 178, 6715-6719 (2007). (Pubitemid 46847393)
65. Chamorro, S. et al. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J. Immunol. 183, 2984-2994 (2009).
66. Muller, W. A. Mechanisms of leukocyte transendothelial migration. Annu. Rev. Pathol. 28, 323-344 (2011).
67. Bouma-ter Steege, J. C. et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin. Cancer Res. 10, 7171-7178 (2004). (Pubitemid 39487702)
68. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003). (Pubitemid 36077915)
69. Detmar, M. et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111, 1-6 (1998). (Pubitemid 28309201)
70. Griffioen, A. W., Damen, C. A., Blijham, G. H. & Groenewegen, G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88, 667-673 (1996). (Pubitemid 26240398)
71. Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H. & Groenewegen, G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 56, 1111-1117 (1996). (Pubitemid 26065408)
72. Bouzin, C., Brouet, A., De Vriese, J., Dewever, J. & Feron, O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 178, 1505-1511 (2007). (Pubitemid 46154621)
73. Min, J. K. et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-κB pathway. Circ. Res. 96, 300-307 (2005).
74. Dirkx, A. E. et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63, 2322-2329 (2003). (Pubitemid 36538644)
75. Bagnato, A. et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 59, 720-727 (1999). (Pubitemid 29076073)
76. Nummer, D. et al. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J. Natl Cancer Inst. 99, 1188-1199 (2007). (Pubitemid 47233069)
77. Shetty, S. et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J. Immunol. 186, 4147-4155 (2011).
78. Schenkel, A. R., Mamdouh, Z., Chen, X., Liebman, R. M. & Muller, W. A. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nature Immunol. 3, 143-150 (2002). (Pubitemid 34141444)
79. Mazanet, M. M. & Hughes, C. C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169, 3581-3588 (2002).
80. Rodig, N. et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33, 3117-3126 (2003). (Pubitemid 37428344)
81. Sata, M. & Walsh, K. TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nature Med. 4, 415-420 (1998). (Pubitemid 28212756)
82. Secchiero, P. & Zauli, G. The puzzling role of TRAIL in endothelial cell biology. Arterioscler. Thromb. Vasc. Biol. 28, e4; author reply e5-e6 (2008). (Pubitemid 351161213)
83. Ma, L. et al. Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance. Proc. Natl Acad. Sci. USA 107, 19461-19466 (2010).
84. Hernandez, G. L. et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 193, 607-620 (2001). (Pubitemid 32539557)
85. Pirtskhalaishvili, G. & Nelson, J. B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44, 77-87 (2000). (Pubitemid 30390068)
86. Huang, X. et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J. Exp. Med. 207, 505-520 (2010).
87. Batista, C. E. et al. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol. Imaging Biol. 11, 460-466 (2009).
88. Riesenberg, R. et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 13, 6993-7002 (2007). (Pubitemid 350276880)
89. Wang, Y. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nature Med. 16, 279-285 (2010).
90. Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999). (Pubitemid 29227522)
91. Choi, J., Enis, D. R., Koh, K. P., Shiao, S. L. & Pober, J. S. T lymphocyte-endothelial cell interactions. Annu. Rev. Immunol. 22, 683-709 (2004). (Pubitemid 38680438)
92. Mulligan, J. K., Day, T. A., Gillespie, M. B., Rosenzweig, S. A. & Young, M. R. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum. Immunol. 70, 375-382 (2009).
93. Mulligan, J. K. & Young, M. R. Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol. Immunother. 59, 267-277 (2009).
94. Nahrendorf, M., Pittet, M. J. & Swirski, F. K. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 121, 2437-2445 (2010).
95. Conejo-Garcia, J. R. et al. Vascular leukocytes contribute to tumor vascularization. Blood 105, 679-681 (2005). (Pubitemid 40070752)
96. De Palma, M., Venneri, M. A., Roca, C. & Naldini, L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Med. 9, 789-795 (2003). (Pubitemid 36749231)
97. Yan, S. F. et al. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J. Biol. Chem. 270, 11463-11471 (1995).
98. Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G. & Levi, B. Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271, 736-741 (1996). (Pubitemid 26034921)
99. Wei, L. H. et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22, 1517-1527 (2003).
100. Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881 (2006).
101. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
102. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
103. Ivy, S. P., Wick, J. Y. & Kaufman, B. M. An overview of small-molecule inhibitors of VEGFR signaling. Nature Rev. Clin. Oncol. 6, 569-579 (2009).
104. Ebos, J. M. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Rev. Clin. Oncol. 8, 210-221 (2011).
105. Quezada, S. A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125-2138 (2008).
106. Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005). (Pubitemid 40354681)
107. Basu, G. D. et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177, 2391-2402 (2006). (Pubitemid 44201000)
108. Escudier, B. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010).
109. Rini, B. I. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137-2143 (2010).
110. Chinnasamy, D. et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953-3968 (2010).
111. Arenberg, D. A. et al. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184, 981-992 (1996).
112. Sgadari, C. et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 89, 2635-2643 (1997). (Pubitemid 27172547)
113. Lasagni, L. et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197, 1537-1549 (2003). (Pubitemid 36682550)
114. Yano, K. et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J. Exp. Med. 203, 1447-1458 (2006). (Pubitemid 43877607)
115. Cavassani, K. A. et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 115, 4403-4411 (2010).
116. Pucci, F. et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114, 901-914 (2009).
117. Muthuswamy, R. et al. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68, 5972-5978 (2008).
118. Baratelli, F. et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 175, 1483-1490 (2005). (Pubitemid 41023048)
119. Ahmadi, M., Emery, D. C. & Morgan, D. J. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68, 7520-7529 (2008).
120. Rodriguez, P. C. et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931-939 (2005). (Pubitemid 41396893)
121. Ohta, A. et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J. Immunol. 183, 5487-5493 (2009).
122. Zarek, P. E. et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251-259 (2008).
123. Hasko, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Rev. Drug Discov. 7, 759-770 (2008).
124. Taylor, A. W. Review of the activation of TGF-β in immunity. J. Leukoc. Biol. 85, 29-33 (2009).
125. Li, Y. et al. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J. Invest. Dermatol. 126, 128-136 (2006). (Pubitemid 43336104)
126. Biancone, L. et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J. Exp. Med. 186, 147-152 (1997). (Pubitemid 27304857)
127. Li, X. et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 69, 1685-1692 (2009).
128. Volpert, O. V. et al. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188, 1039-1046 (1998). (Pubitemid 28443327)
129. Fukushi, J., Ono, M., Morikawa, W., Iwamoto, Y. & Kuwano, M. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J. Immunol. 165, 2818-2823 (2000). (Pubitemid 30660733)
130. Yamaji-Kegan, K., Su, Q., Angelini, D. J. & Johns, R. A. IL-4 is proangiogenic in the lung under hypoxic conditions. J. Immunol. 182, 5469-5476 (2009).
131. Eubank, T. D., Galloway, M., Montague, C. M., Waldman, W. J. & Marsh, C. B. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J. Immunol. 171, 2637-2643 (2003). (Pubitemid 37025577)
132. Shojaei, F. et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106, 6742-6747 (2009).
133. Okazaki, T. et al. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int. Immunol. 18, 1-9 (2006). (Pubitemid 43057031)
134. Bronte, V. & Zanovello, P. Regulation of immune responses by l-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005). (Pubitemid 41113195)
135. Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y. & Saito, T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl Acad. Sci. USA 93, 13119-13124 (1996). (Pubitemid 26382779)
136. Spinella, F., Rosano, L., Di Castro, V., Natali, P. G. & Bagnato, A. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J. Biol. Chem. 279, 46700-46705 (2004). (Pubitemid 39523128)
137. Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339-1346 (2001).
138. Lin, Y. L., Liang, Y. C. & Chiang, B. L. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J. Leukoc. Biol. 82, 1473-1480 (2007).
139. Fischer, C., Mazzone, M., Jonckx, B. & Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nature Rev. Cancer 8, 942-956 (2008).
140. Sutmuller, R. P. et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116, 485-494 (2006). (Pubitemid 43228366)
141. Jarnicki, A. G. et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180, 3797-3806 (2008).
142. Macedo, L. et al. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am. J. Pathol. 171, 1774-1788 (2007).
143. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457-1464 (2009).